CanCure LLC

CB-10

A Clinic-Ready Novel Class IO therapeutic Antibody Empowers Patients to Fight Multiple Types of Cancer

Contact: cancurellc@canzxbio.com
www.cancurellc.com

CB-10 Executive Summary

CanCure LLC

- **The problem:** Tumors overexpress MIC and produce soluble MIC (sMIC) to disable patient's immune system and ability to fight cancer
- **The solution:** CB-10 is a clinic-ready, monoclonal IgG1 antibody which captures sMIC and converts it into an immune reviving molecule to empower patients own immune system to fight off cancer.
- CB-10 has completed preclinical development and is **clinic-ready**
  - MOA, IND-enabling safety studies completed; IND to be filed in Q2 2025
- 2 clinical trials are fully funded through **NON-diluted** Awards and academic centers to treat the 1st patient in Summer 2025
- Drug Manufacturing will be completed by April 2025
- To date, CB-10 has been developed by CanCure LLC solely through **non-dilutive** capital (Founder's and NIH grants)
- CanCure LLC is seeking an investment of > $1.5 M to help manufacture sufficient CB-10 for expanding clinical testing
- CanCure LLC would consider options for a larger investment to enable parallel company-sponsored trials to expand patient population, speed up the program development, and more disease indications
- CB-10 outperforms its competitor preclinically
- CB-10 is the leading asset of CanCure

CB-10 Novel Mechanism of Action - One molecule, multi-Modal actions

Cancer Cell:
Produce sMIC
to suppress immunity



- Immune dysfunction
- Tumor metastasis
- Poor response to current immunotherapy

CB-10:
transforms sMIC to
an immune activator

CB-10/sMIC
complex



OUTCOME:
Immune Revamping (NK and CD8 T)
Tumor Elimination

NK



- **Co-stimulate NK**
- **Enhance "memory" or stemness**
- **ADCC**

CD8T



- **Co-stimulate CD8T**
- **Enhance memory**
- **Enhanced effector function**

Tumor elimination

CB-10: humanized B10G5, hIgG1

Social and Economical Impact

CanCure LLC

Social Impact

CB-10 could fulfill the large global unmet need for cancer treatment, prolong many millions of lives

Economic Impact

- Counting all cancer patients, only a small population (12.5%) of ALL cancer patients can benefit from current IO drugs; but the Global IO drug market is about $138.87Bn in 2024, projected $224.30Bn by 2030, 8.3%CAGR

- CB-10 can not only capture all the IO drug failures but also makes current IO drugs work better.

- CB-10 capture even 25% of the Global Cancer Market, ~$276Bn annual revenue

Benefit (12.5%)
2024 Market: $138.87Bn
2030 Market: $224.50Bn



NOT Benefit,
Unmet need
87.5%

All Cancers

JAMA Netw Open. PMID: 31050774

The CB-10 target MIC expression is prevalent in multiple solid tumor types with minimal presence in normal tissues

TUMOR (>90%)



Unpublished (CanCure)

NORMAL TISSUE



Blery M. Open Res Eur. 2021 Oct 27:1:107. PMID 35967081

- Consistent with the lack of MIC expression in normal tissues, GLP toxicity studies demonstrated no significant pathologic findings at the highest dose level tested (100 mg/kg)

CB-10 demonstrates monotherapy activity in multiple preclinical tumor models

❖ **Effective with low dose (1 mg/Kg) and outperforms CLN-619**



CLN-619
1 mg/Kg



CLN-619 is an IgG1 monoclonal antibody which reduces MIC shedding. The main MOA of CLN-619 is ADCC.

❖ **Long lasting cure and prevent tumor re-growth**



Model system: Syngeneic TRAMP-C2-MICB tumor, s.c. (Unpublished)

CB-10 monotherapy leads to complete regressions in a carcinogen-induced metastatic bladder tumor model

Mice (engineered*) were fed with bladder-specific carcinogen (BBN)



- Primary tumors were induced in the bladder
- Tumor metastasized to liver, lung, LN, and kidney

2 wks CB-10 therapy (i.p. twice weekly)

Burdens of primary tumor and metastatic tumor were reduced

4 wks CB-10 therapy (i.p. twice weekly)

Primary tumor and metastatic tumors were eradicated

***Note: MIC genes do not naturally exist in mice. Mice were engineered to have a MIC gene integrated in the genome.**

CB-10 Clinical Development Plan

CanCure LLC



Completed (non-diluted fund):

- Pre-clinical efficacy
  Dose response in efficacy
  MOA
- IND-enabling GLP tox
- MCB and GMP Process Development
- Phase I/II Protocol Development

Raise US$ 1.5-20 M

Fund Secured (Grants Award, non-diluted) and Collaborating with Academic Cancer Center(s):

- Phase I prostate cancer
- Phase I/II Sarcoma

- More undiluted funding opportunities for other solid tumor types

Manufacturing Sufficient Clinical Drug to Treat More Patients and Expand the technology Platform and Indications

Impact and Revenue Forecast

Social Impact

CB-10 could fulfill the large Global unmet need for cancer patients, prolong lives

Economic Impact

- Approved IO drugs with ONLY a small population (8%) of patients can benefit, but the Global IO market is about $138.87Bn in 2024, projected $224.30Bn by 2030, 8.3%CAGR
- CB-10 can not only capture all the IO drug failures but also makes current IO drugs work better.
- CB-10 captures even 10% of the Global Cancer Market, ~$140Bn annual revenue

Early-stage revenue stream: Technology out-licensing or partnership

Historical Deal Size (total in $Bn, based on 2023 data)

- At Phase I clinical stage out-licensing: > $2 Bn
- At Phase II clinical stage out-licensing $2.8-22 Bn

(source: *www.nature.com/biopharmdeal | December 2023 | B45*)

Ask for US$1.5 - 20M to speed up producing sufficient drugs to expand the technology platform and clinical indications